- Resmed (RMD, Financial) appoints Salli Schwartz as Chief Investor Relations Officer effective April 21, 2025.
- Salli Schwartz brings over 20 years of experience from leading roles at Illumina, MSCI, and Moody's.
- The appointment aligns with Resmed's 2030 strategy to enhance shareholder value and improve global health outcomes.
Resmed (RMD, ASX: RMD), a global leader in health technology, has announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. Schwartz will report directly to CEO Mick Farrell and lead the company's global investor relations efforts.
Schwartz joins Resmed from Illumina, where she served as Head of Investor Relations. At Illumina, she was responsible for managing shareholder engagement and corporate strategy communications and was an integral part of the Corporate Social Responsibility Executive Steering Committee.
Prior to her role at Illumina, Schwartz held significant positions at MSCI, including Head of Investor Relations and Treasurer. During her tenure, she managed over $2 billion in cash and short-term investments and $4 billion in debt. Her career also includes leadership roles at Moody's Corporation and Citigroup.
This strategic appointment is part of Resmed's broader 2030 vision to drive shareholder value while empowering 500 million people worldwide through better sleep and breathing health solutions.
Resmed is renowned for its pioneering health technologies and innovative solutions that utilize AI-powered digital health platforms to deliver personalized healthcare within the comfort of one's home.
